Curevo Vaccine Announces $26 Million Series A1 Financing To Support Clinical Development Of Next-Generation Subunit Vaccines

Nov 16, 2022•over 2 years ago

Amount Raised

$26 Million

Round Type

series a

BothellBiotechnology

Investors

Adjuvant CapitalRa Capital ManagementJanus Henderson Investors

Description

Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.

Company Information

Company

Curevo Vaccine

Location

Bothell, Washington, United States

About

Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Curevo Vaccine Announces $26 Million Series A1 Financing To Support Clinical Development Of Next-Generation Subunit Vaccines

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information